Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary
The DOI matches its Crossref record; 123 of the 130 references it cites were found in a registry or an index.
Abstract
The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders should be addressed, and pharmacologic therapy initiated based on a patient's risk for atherosclerotic cardiovascular disease (ASCVD). Patients at extreme ASCVD risk should be treated with high-intensity statin therapy to achieve a goal low-density lipoprotein cholesterol (LDL-C) of <55 mg/dL, and those at very high ASCVD risk should be treated to achieve LDL-C <70 mg/dL. Treatment for moderate and high ASCVD risk patients may begin with a moderate-intensity statin to achieve an LDL-C <100 mg/dL, while the LDL-C goal is <130 mg/dL for those at low risk. In all cases, treatment should be intensified, including the addition of other LDL-C-lowering agents (i.e., proprotein convertase subtilisin/kexin type 9 inhibitors, ezetimibe, colesevelam, or bempedoic acid) as needed to achieve treatment goals. When targeting triglyceride levels, the desirable goal is <150 mg/dL. Statin therapy should be combined with a fibrate, prescription-grade omega-3 fatty acid, and/or niacin to reduce triglycerides in all patients with triglycerides ≥500 mg/dL, and icosapent ethyl should be added to a statin in any patient with established ASCVD or diabetes with ≥2 ASCVD risk factors and triglycerides between 135 and 499 mg/dL to prevent ASCVD events. Management of additional risk factors such as elevated lipoprotein(a)…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accumulating evidence favors the need to assess apo Becontaining lipoproteins to account for remnant lipoproteins and small dense lipoproteins responsible for residual ASCVD risk not seen with a standard lipid panel of total cholesterol, LDL-C, and HDL-C.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [314]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175 · cited 14×
“adults, 112 mg/dL (3), is higher than the recommended LDL-C goal of <100 mg/dL for those with moderate ASCVD risk and well above the goals for people at high risk of ASCVD (1).”
InfluentialCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · cited 6×
“Outcomes trials with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in which achieved LDL-C levels were substantially lower than those in statin trials further reinforced the notion that “lower is better” (24,25).”
InfluentialThe Health consequences of smoking—50 years of progress : a report of the Surgeon General
Lushniak, B. D., Samet, J. M., Pechacek, T. F., Norman, L., & Taylor, P. A. (2014) · Cited by 4,990
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationAlirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634 · cited 5×
“Outcomes trials with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in which achieved LDL-C levels were substantially lower than those in statin trials further reinforced the notion that “lower is better” (24,25).”
InfluentialEstruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800389 · Cited by 3,616 · cited 1×
“Several dietary patterns, however, appear to be beneficial, including the Mediterranean and Dietary Approaches to Stop Hypertension (DASH), which improve cardiovascular outcomes (40,41).”
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439 · cited 1×
“However, epidemiologic evidence and findings from the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial study support a cardioprotective role of HDL-C (1,38,39).”
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 2×
“Outcomes studies with fibrates have had mixed results, especially in statin-treated populations and in individuals treated with fibrates who have less severe triglyceride and HDL-C abnormalities (32,35,39,93).”
(2020) · PubMed · Cited by 2,642
Cappuccio, F. P., Cooper, D., D'Elia, L., Strazzullo, P., & Miller, M. A. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr007 · Cited by 2,146
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Ridker, P. M., Buring, J. E., Rifai, N., & Cook, N. R. (2007) · JAMA · doi:10.1001/jama.297.6.611 · Cited by 1,814
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Intensive Lifestyle Changes for Reversal of Coronary Heart Disease
Ornish, D. (1998) · JAMA · doi:10.1001/jama.280.23.2001 · Cited by 1,730
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668 · cited 1×
“However, large-scale clinical trials such as Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides (AIM-HIGH) have not demonstrated cardiovascular benefit with niacin when individuals are well-controlled on statin therapy, and in some instances, the combination may increase the side effec…”
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Self-citationTriglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
Self-citationPreiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390
Omega‐3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?
Calder, P. C. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04374.x · Cited by 1,347
de Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., Rouleau, J.-L., Pedersen, T. R., Gardner, L. H., Mukherjee, R., et al. (2004) · JAMA · doi:10.1001/jama.292.11.1307 · Cited by 1,333 · cited 4×
“Very-high-risk criteria include established or recent hospitalization for acute coronary syndrome (ACS) or for coronary, carotid, or peripheral vascular disease with a 10-year ASCVD risk >20%.”
Influentialn-3 fatty acids and serum lipoproteins: human studies
Harris, W. (1997) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/65.5.1645s · Cited by 1,243
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226 · cited 1×
“Statin intolerance (see Section VII, Managing Statin Intolerance and Safety) or the inability to reach LDL-C goal may limit the use of intensive statin therapy in some patients (69).”
A Prospective Study of Sleep Duration and Coronary Heart Disease in Women
Ayas, N. T., White, D. P., Manson, J. E., Stampfer, M. J., Speizer, F. E., Malhotra, A., & Hu, F. B. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.2.205 · Cited by 1,155 · cited 1×
“Evidence supports an association of 6 to 8 hours of sleep per night with a reduction in cardiometabolic risk factors, whereas sleep deprivation aggravates insulin resistance, hypertension, hyperglycemia, and dyslipidemia, and increases inflammatory cytokines (52-57).”
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094 · cited 10×
“HeFH affects approximately 1 in 250 to 500 persons, whereas HoFH occurs at a rate of 1 to 4 per 1 million, although rates as high as 1/160,000 have been reported in some genetically isolated populations (1,16).”
InfluentialSelf-citationThe UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M. (2001) · Clinical Science · doi:10.1042/cs20000335 · Cited by 1,084
A meta-analysis of alcohol consumption and the risk of 15 diseases
Corrao, G. (2004) · Preventive Medicine · doi:10.1016/j.ypmed.2003.11.027 · Cited by 1,077 · cited 1×
“Although some meta-analyses have shown decreased cardiovascular outcomes in persons who drink limited quantities of alcohol compared to abstainers (60,61), drinking alcohol is not recommended as an intervention due to potential adverse effects.”
Jones, P., Kafonek, S., Laurora, I., & Hunninghake, D. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00965-x · Cited by 1,067
Bazzano, L. A., He, J., Ogden, L. G., Loria, C. M., Vupputuri, S., Myers, L., & Whelton, P. K. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/76.1.93 · Cited by 1,035
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037184 · Cited by 984
Self-citationAssociation of usual sleep duration with hypertension: the Sleep Heart Health Study
Gottlieb, D. J., Redline, S., Nieto, F. J., Baldwin, C. M., Newman, A. B., Resnick, H. E., & Punjabi, N. M. (2006) · Sleep · doi:10.1093/sleep/29.8.1009 · Cited by 947 · cited 1×
“Evidence supports an association of 6 to 8 hours of sleep per night with a reduction in cardiometabolic risk factors, whereas sleep deprivation aggravates insulin resistance, hypertension, hyperglycemia, and dyslipidemia, and increases inflammatory cytokines (52-57).”
Robins, S. J., Collins, D., Wittes, J. T., Papademetriou, V., Deedwania, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., Wexler, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 921
Goff, D. C., Lloyd‐Jones, D. M., Bennett, G. C., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D. A., O’Donnell, C. J., et al. (2014) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · Cited by 851
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807 · cited 1×
“In clinical trials, BA reduced LDL-C by 15 to 24% (128-131).”
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., Goldstein, L. B., Chin, C., Tannock, L. R., Miller, M., Raghuveer, G., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 738
Self-citationLipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Diabetes Care · doi:10.2337/dc08-9018 · Cited by 707
Self-citationFerence, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J., Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., et al. (2019) · JAMA · doi:10.1001/jama.2018.20045 · Cited by 703 · cited 1×
“Hypertriglyceridemia may present with increased numbers or concentrations of atherogenic small, dense LDL particles and apo B-100-associated triglyceride-rich lipoprotein remnant cholesterol particles, which increase ASCVD risk (92).”
Giugliano, R. P., Pedersen, T. R., Park, J.-G., De Ferrari, G. M., Gaciong, Z. A., Ceska, R., Toth, K., Gouni-Berthold, I., Lopez-Miranda, J., Schiele, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32290-0 · Cited by 682
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Self-citationHypertriglyceridemia: its etiology, effects and treatment
Yuan, G., Al-Shali, K. Z., & Hegele, R. A. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060963 · Cited by 624 · cited 1×
“Severe hypertriglyceridemia (triglycerides >500 mg/dL) increases the risk of acute pancreatitis and chylomicronemia syndrome (1,13).”
Association between Reduced Sleep and Weight Gain in Women
Patel, S. R., Malhotra, A., White, D. P., Gottlieb, D. J., & Hu, F. B. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj280 · Cited by 617
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598 · cited 2×
“However, in view of the demonstrated benefits of statin therapy for prevention of ASCVD, the leading cause of death in patients with diabetes, the risk for new onset diabetes or modest worsening of glycemic control in established diabetes does not justify withholding statins in patients with significant ASCVD risk (88…”
Self-citationVery Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events
Boekholdt, S. M., Hovingh, G. K., Mora, S., Arsenault, B. J., Amarenco, P., Pedersen, T. R., LaRosa, J. C., Waters, D. D., DeMicco, D. A., Simes, R. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.615 · Cited by 581
Framingham risk score and prediction of lifetime risk for coronary heart disease
Lloyd-Jones, D. M., Wilson, P. W. F., Larson, M. G., Beiser, A., Leip, E. P., D'Agostino, R. B., & Levy, D. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.03.023 · Cited by 566
Willeit, P., Ridker, P. M., Nestel, P. J., Simes, J., Tonkin, A. M., Pedersen, T. R., Schwartz, G. G., Olsson, A. G., Colhoun, H. M., Kronenberg, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31652-0 · Cited by 564 · cited 1×
“A Lp(a) level >50 mg/dL is associated with increased risk of recurrent events in patients on statin therapy (117).”
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Self-citationChiavaroli, L., Viguiliouk, E., Nishi, S., Blanco Mejia, S., Rahelić, D., Kahleová, H., Salas-Salvadó, J., Kendall, C., & Sievenpiper, J. (2019) · Nutrients · doi:10.3390/nu11020338 · Cited by 548 · cited 2×
“Generally, reduced fat dairy products, fish, lean meats, and skinless poultry are preferable to traditional high fat alternatives, and salt intake should be decreased (41,42).”
Wilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.04.010 · Cited by 518
Chaput, J., Després, J., Bouchard, C., & Tremblay, A. (2007) · Obesity · doi:10.1038/oby.2007.512 · Cited by 498 · cited 1×
“Evidence supports an association of 6 to 8 hours of sleep per night with a reduction in cardiometabolic risk factors, whereas sleep deprivation aggravates insulin resistance, hypertension, hyperglycemia, and dyslipidemia, and increases inflammatory cytokines (52-57).”
The intriguing relationship between coronary heart disease and mental disorders
De Hert, M., Detraux, J., & Vancampfort, D. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.1/mdehert · Cited by 489
Goldberg, A. C., Leiter, L. A., Stroes, E. S. G., Baum, S. J., Hanselman, J. C., Bloedon, L. T., Lalwani, N. D., Patel, P. M., Zhao, X., & Duell, P. B. (2019) · JAMA · doi:10.1001/jama.2019.16585 · Cited by 481
Trimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease
Zeisel, S. H., & Warrier, M. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064732 · Cited by 475 · cited 1×
“One mechanism might be that meat and dairy cause higher levels of trimethylamine N-oxide, which has been associated with development and progression of atherosclerosis, primarily by altering the gut microbiome (47).”
BARTER, P. J., BALLANTYNE, C. M., CARMENA, R., CABEZAS, M. C., CHAPMAN, M. J., COUTURE, P., DE GRAAF, J., DURRINGTON, P. N., FAERGEMAN, O., FROHLICH, J., et al. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01616.x · Cited by 464
Self-citationBallantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.002 · Cited by 422
Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease
Navar-Boggan, A. M., Peterson, E. D., D’Agostino, R. B., Neely, B., Sniderman, A. D., & Pencina, M. J. (2015) · Circulation · doi:10.1161/circulationaha.114.012477 · Cited by 407
Davidson, M. H., Stein, E. A., Bays, H. E., Maki, K. C., Doyle, R. T., Shalwitz, R. A., Ballantyne, C. M., & Ginsberg, H. N. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.018 · Cited by 385 · cited 1×
“These agents reduce triglycerides by approximately 20 to 45%, depending on baseline triglyceride levels (34,95,99,100).”
Self-citationon behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-1951-1 · Cited by 371 · cited 1×
“However, despite initially and reversibly increasing serum creatinine, fenofibrate reduced albuminuria and slowed eGFR loss over 5 years (133).”
Mach, F., Ray, K. K., Wiklund, O., Corsini, A., Catapano, A. L., Bruckert, E., De Backer, G., Hegele, R. A., Hovingh, G. K., Jacobson, T. A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy182 · Cited by 370
Self-citationBallantyne, C. M., Laufs, U., Ray, K. K., Leiter, L. A., Bays, H. E., Goldberg, A. C., Stroes, E. S., MacDougall, D., Zhao, X., & Catapano, A. L. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319864671 · Cited by 358
Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment
Raal, F. J., & Santos, R. D. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.02.019 · Cited by 349
Saito, Y., Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.06.003 · Cited by 316 · cited 1×
“Several studies including the long-term follow up of the Helsinki Heart Study, the Japan EPA Lipid Intervention Study, and the Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT), showed that treating patients with elevated triglycerides significantly improved cardiovascular outcomes and/or lowe…”
Cederberg, H., Stančáková, A., Yaluri, N., Modi, S., Kuusisto, J., & Laakso, M. (2015) · Diabetologia · doi:10.1007/s00125-015-3528-5 · Cited by 316
Trends in the epidemiology of cardiovascular disease in the UK
Bhatnagar, P., Wickramasinghe, K., Wilkins, E., & Townsend, N. (2016) · Heart · doi:10.1136/heartjnl-2016-309573 · Cited by 310
Gepner, A. D., Young, R., Delaney, J. A., Tattersall, M. C., Blaha, M. J., Post, W. S., Gottesman, R. F., Kronmal, R., Budoff, M. J., Burke, G. L., et al. (2015) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.114.002262 · Cited by 287
Self-citationDiscrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a)
Willeit, P., Kiechl, S., Kronenberg, F., Witztum, J. L., Santer, P., Mayr, M., Xu, Q., Mayr, A., Willeit, J., & Tsimikas, S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.061 · Cited by 286 · cited 1×
“Assessment and Management of Elevated Lipoprotein(a) Increased Lp(a) is the most common genetic dyslipidemia, with a prevalence in the general population of 20%, and is an independent, genetic, and causal risk factor for ASCVD (MI, stroke, peripheral arterial disease, recurrent events, and calcific aortic stenosis) (1…”
Kelley, G. A., & Kelley, K. S. (2009) · Preventive Medicine · doi:10.1016/j.ypmed.2008.10.010 · Cited by 263 · cited 1×
“Therefore, in addition to aerobic activity, muscle-strengthening activity is recommended at least 2 days a week (51).”
Crowe, F. L., Appleby, P. N., Travis, R. C., & Key, T. J. (2013) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.044073 · Cited by 263
Effects of Icosapent Ethyl on Total Ischemic Events
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.032 · Cited by 259
Self-citationMancini, G. B. J., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D., Pearson, G. J., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.01.003 · Cited by 250
Ridker, P. M., Morrow, D. A., Rose, L. M., Rifai, N., Cannon, C. P., & Braunwald, E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.080 · Cited by 236
Abstract #100: Acth-Secreting Pheochromocytoma
Kalia-Reynolds, M., Giordano, J., Kalia-Reynolds, I., & Houston, C. (2015) · Endocrine Practice · doi:10.1016/s1530-891x(20)42300-6 · Cited by 208
Pownall, H. J., Brauchi, D., Kilinç, C., Osmundsen, K., Pao, Q., Payton-Ross, C., Gotto, A. M., & Ballantyne, C. M. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(98)00301-3 · Cited by 179 · cited 1×
“Over-the-counter fish oil dietary supplements are not FDA-approved for lowering triglycerides and are not recommended for this purpose because they contain very low amounts of polyunsaturated omega3 fatty acids as well as trans fatty acids and saturated fat (111-113).”
Qu, H., Guo, M., Chai, H., Wang, W., Gao, Z., & Shi, D. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009835 · Cited by 178
Acute and Chronic Effects of Cocaine on Cardiovascular Health
Kim, S. T., & Park, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030584 · Cited by 173
Sahebkar, A., Reiner, Ž., Simental‐Mendía, L. E., Ferretti, G., & Cicero, A. F. G. (2016) · Metabolism · doi:10.1016/j.metabol.2016.08.007 · Cited by 157
Inadequate Sleep as a Contributor to Obesity and Type 2 Diabetes
McNeil, J., Doucet, É., & Chaput, J. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.02.060 · Cited by 144
Tenkanen, L., Mänttäri, M., Kovanen, P. T., Virkkunen, H., & Manninen, V. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.7.743 · Cited by 129
The Effect of Aggressive Versus Standard Lipid Lowering by Atorvastatin on Diabetic Dyslipidemia
The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1335 · Cited by 128
Esselstyn, C. B., Gendy, G., Doyle, J., Golubić, M., & Roizen, M. F. (2014) · PubMed · Cited by 127
Sin, N. L. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0792-z · Cited by 125
Secondary Causes of Dyslipidemia
Vodnala, D., Rubenfire, M., & Brook, R. D. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.062 · Cited by 123
Levinger, I., Goodman, C., Hare, D. L., Jerums, G., & Selig, S. (2007) · Diabetes Care · doi:10.2337/dc07-0841 · Cited by 122
Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date.
Gaddi, A. V., Cicero, A. F. G., Odoo, F. O., Poli, A. A., & Paoletti, R. (2007) · PubMed Central · Cited by 113
Prescription Drug Use Among Adults Aged 40-79 in the United States and Canada.
Hales, C. M., Servais, J., Martin, C. B., & Kohen, D. (2019) · PubMed · Cited by 113
Costanzo, S., Castelnuovo, A. F. D., Donati, M. B., Iacoviello, L., & de Gaetano, G. (2010) · Circulation · doi:10.1161/circulationaha.109.865840 · Cited by 112
Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events
Suk Danik, J., Rifai, N., Buring, J. E., & Ridker, P. M. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.009 · Cited by 108
Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects
Vargas, J. I., Arrese, M., Shah, V. H., & Arab, J. P. (2017) · Current Gastroenterology Reports · doi:10.1007/s11894-017-0584-7 · Cited by 94
Determining Triglyceride Reductions Needed for Clinical Impact in Severe Hypertriglyceridemia
Christian, J. B., Arondekar, B. V., Buysman, E. K., Jacobson, T. A., Snipes, R., & Horwitz, R. I. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.09.018 · Cited by 85
Niacin, an old drug with a new twist
Song, W.-L., & FitzGerald, G. A. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r040592 · Cited by 69
Toth, P. P., Fazio, S., Wong, N. D., HULL, M. L., & Nichols, G. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13921 · Cited by 69
Self-citationBempedoic acid: effects on lipoprotein metabolism and atherosclerosis
Burke, A. C., Telford, D. E., & Huff, M. W. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000565 · Cited by 68
Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk
Tsimikas, S. (2016) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000237 · Cited by 62
Sever, P. S., Dahlöf, B., & Poulter, N. R. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00278-2 · Cited by 58
Robins, S. J., Collins, D. E., & Wittes, J. T. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00369-5 · Cited by 46
Niacin and heart disease prevention: Engraving its tombstone is a mistake
Superko, H. R., Zhao, X.-Q., Hodis, H. N., & Guyton, J. R. (2017) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.08.005 · Cited by 46
for the BIP Study Group, Arbel, Y., Klempfner, R., Erez, A., Goldenberg, I., Benzekry, S., Shlomo, N., Fisman, E. Z., & Tenenbaum, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0332-6 · Cited by 40
Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity
Pokrovsky, S. N., Afanasieva, O. I., Safarova, M. S., Балахонова, Т. В., Matchin, Y. G., Adamova, I. Y., Konovalov, G. A., & Владиславович, Е. М. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.004 · Cited by 40
Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence
Sherratt, S. C. R., Lero, M., & Mason, R. P. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000665 · Cited by 33 · cited 1×
“Over-the-counter fish oil dietary supplements are not FDA-approved for lowering triglycerides and are not recommended for this purpose because they contain very low amounts of polyunsaturated omega3 fatty acids as well as trans fatty acids and saturated fat (111-113).”
Organic Substrate and Electrolyte Solutions for Oral Rehydration in Diarrhea
Desjeux, J. F., Nath, S., & Taminiau, J. (1994) · Annual Review of Nutrition · doi:10.1146/annurev.nu.14.070194.001541 · Cited by 31
Zafrir, B., Jubran, A., Hijazi, R., & Shapira, C. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.03.086 · Cited by 31
Effect of Aspirin on Lipoprotein(a) in Patients With Ischemic Stroke
Ranga, G. S., Kalra, O. P., Tandon, H., Gambhir, J. K., & Mehrotra, G. (2007) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2007.05.003 · Cited by 28
A plant-based diet and stroke.
Campbell, T. M. (2017) · PubMed Central · doi:10.11909/j.issn.1671-5411.2017.05.010 · Cited by 22
Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype
Artemeva, N., Safarova, M. S., Владиславович, Е. М., Afanasieva, O. I., Dmitrieva, O. A., & Pokrovsky, S. N. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.008 · Cited by 21
Trimethylamine N-Oxide, the Microbiome, and Heart and Kidney Disease
Warrier, M., & Zeisel, S. H. (2022) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/w31x-e044 · Cited by 15
Nerbrand, C., Nyberg, P., Nordström, L., & Samsioe, G. (2002) · Maturitas · doi:10.1016/s0378-5122(01)00302-4 · Cited by 11
Woo, Y., Shin, J.-S., Shim, C. Y., Kim, J., Kim, B., Park, S., Chang, H., Hong, G., Ko, Y., Kang, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205006 · Cited by 11
Early childhood environment and dementia
Hall, K. S., & Hendrie, H. C. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60767-3 · Cited by 10
Ganga, H. V., Maan, A., & Heist, E. K. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0974-y · Cited by 3
(1995) · PubMed
Research works printed but not linked: 4
- Sever, 2003, J Am Coll Cardiol., 361, 1149
- Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Cardiovasc Diabetol., 366, 1849
- 2000, Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease, N Engl J Med., 102, 21
- Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet., 376, 1670, 10.1016/S0140-6736(10)61350-5 · DOI · Paper page
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationSamson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Lipoprotein(a) and cardiovascular disease
Nordestgaard, B. G., & Langsted, A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01308-4 · Cited by 288
Ten things to know about ten cardiovascular disease risk factors
Bays, H. E., Taub, P. R., Epstein, E., Michos, E. D., Ferraro, R. A., Bailey, A. L., Kelli, H. M., Ferdinand, K. C., Echols, M. R., Weintraub, H., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100149 · Cited by 274
Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds
Tsimikas, S., & Marcovina, S. M. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.06.019 · Cited by 176
Metadata
- Authors
- Handelsman, Y., Jellinger, P. S., Guerin, C. K., Bloomgarden, Z. T., Brinton, E. A., Budoff, M. J., Davidson, M. H., Einhorn, D., Fazio, S., Fonseca, V. A., Garber, A. J., Grunberger, G., Krauss, R. M., Mechanick, J. I., Rosenblit, P. D., Smith, D. A., & Wyne, K. L.
- Affiliations
- University of Miami (US)
- University of California San Diego (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of California, Los Angeles (US)
- University of Chicago (US)
- Oregon Health & Science University (US)
- Tulane University (US)
- Baylor College of Medicine (US)
- Oakland University (US)
- University of California, San Francisco (US)
- University of California, Irvine (US)
- The Ohio State University Wexner Medical Center (US)
- Corresponding author
- Handelsman, Yehuda
- ORCID
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 26
- Issue
- 10
- Pages
- 1196-1224
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W3095590613
- Cited by
- 248
- References
- 130
- Citations by year
- 2026: 20 · 2025: 36 · 2024: 58 · 2023: 50 · 2022: 57 · 2021: 26 · 2020: 1
- FWCI
- 30.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- dyslipidemia management, atherosclerotic cardiovascular disease prevention, LDL cholesterol targets, high-intensity statin therapy, PCSK9 inhibitors, ezetimibe, colesevelam, bempedoic acid, triglyceride-lowering therapy, fibrates, omega-3 fatty acids, nicotinic acid, icosapent ethyl, lipoprotein(a), statin intolerance, lifestyle therapy, cardiovascular risk stratification
- MeSH terms
- Endocrinologists, Algorithms, Anticholesteremic Agents, Cardiovascular Diseases, Humans, Risk Factors, United States, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Consensus, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.